Survival analysis by tumor response from real-world data in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08).

Yosuke Kito,Eisuke Inoue,Yusuke Akamaru,Masazumi Takahashi,Jin Matsuyama,Hiroshi Yabusaki,Akitaka Makiyama,Takahisa Suzuki,Masahiro Tsuda,Hisateru Yasui,Naoki Hirabayashi,Atsushi Takeno,Hisato Kawakami,Hiroyuki Okuda,Takashi Yoshioka,Junji Kawada,Yasuhiro Kodera,Wataru Ichikawa,Masashi Fujii,Yu Sunakawa

Survival analysis by tumor response from real-world data in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08).

2021

4044Background: The phase III ATTRACTION-2 trial demonstrated survival benefit of nivolumab (Nivo) as third- or later-line treatment in previously treated advanced gastric or gastroesophageal junct...

Keywords:

real world data
advanced gastric cancer
Oncology
tumor response
Nivolumab
Medicine
Internal medicine
previously treated
Survival analysis
survival benefit

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations